Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis
The clinical course and prognostic factors of HER2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. The aim of this study was to determine prognostic factors associated with HER2-positive patients who develop brain metastases. This...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2015-01, Vol.149 (1), p.277-284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 1 |
| container_start_page | 277 |
| container_title | Breast cancer research and treatment |
| container_volume | 149 |
| creator | Hayashi, Naoki Niikura, Naoki Masuda, Norikazu Takashima, Seiki Nakamura, Rikiya Watanabe, Ken-ichi Kanbayashi, Chizuko Ishida, Mayumi Hozumi, Yasuo Tsuneizumi, Michiko Kondo, Naoto Naito, Yoichi Honda, Yayoi Matsui, Akira Fujisawa, Tomomi Oshitanai, Risa Yasojima, Hiroyuki Yamauchi, Hideko Saji, Shigehira Iwata, Hiroji |
| description | The clinical course and prognostic factors of HER2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. The aim of this study was to determine prognostic factors associated with HER2-positive patients who develop brain metastases. This retrospective study assessed the largest dataset to date of 432 HER2-positive patients who were diagnosed with brain metastases from 24 institutions of the Japan Clinical Oncology Group, Breast Cancer Study Group. The median age of the 432 patients was 54 years (range, 20–86 years). Of the patients, 162 patients (37.5 %) had ER-positive/HER2-positive (ER+HER2+) breast cancer, and 270 (62.5 %) had ER-negative/HER2-positive (ER−HER2+) breast cancer. The median brain metastasis-free survival period from primary breast cancer was 33.5 months in both groups. The median survival after developing brain metastasis was 16.5 and 11.5 months in the ER+HER2+ and ER−HER2+ groups, respectively, (
p
= 0.117). Patients with >3 brain metastases had significantly shorter overall survival in both ER+HER2+ (
p
|
| doi_str_mv | 10.1007/s10549-014-3237-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652397584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A409979129</galeid><sourcerecordid>A409979129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c606t-aedde120c5996051f7e2c366f6578020d81f63bd52995d9684516a43d890163d3</originalsourceid><addsrcrecordid>eNp1kk9rFTEUxQdR7LP6AdxIQBA3U_NnkkzcldJaoaCIrkNecue9lJlkTDItXfjdm-er2oqSRSD5ncM9l9M0Lwk-IhjLd5lg3qkWk65llMlWPmpWhEvWSkrk42aFiZCt6LE4aJ7lfIkxVhKrp80B5Zz2mJJV8-NzipsQc_EWDcaWmDKKAzo__ULbOWZf_BWgdQKTC7ImWEhoNsVDKBldbyNycAVjnCtifEATlAqa7PN7ZNC0jNW2olWUoKSYZ7A_DU0w402lnjdPBjNmeHF3Hzbfzk6_npy3F58-fDw5vmitwKK0BpwDQrHlSgnMySCBWibEILisMbDrySDY2nGqFHdK9B0nwnTM9aqugDl22Lzd-84pfl8gFz35bGEcTYC4ZE0Ep0xJ3ncVff0XehmXVOfdUZ3gnHW0_0NtzAjahyGWZOzOVB93WCmpCFWVOvoHVY-DydsYYPD1_YHgzT3BFsxYtjmOS_Ex5Icg2YO2bjUnGPSc_GTSjSZY77qh993QtRt61w0tq-bVXbJlPYH7rfhVhgrQPZDrV9hAuhf9v663ru3CZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1646553428</pqid></control><display><type>article</type><title>Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Hayashi, Naoki ; Niikura, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Yamauchi, Hideko ; Saji, Shigehira ; Iwata, Hiroji</creator><creatorcontrib>Hayashi, Naoki ; Niikura, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Yamauchi, Hideko ; Saji, Shigehira ; Iwata, Hiroji</creatorcontrib><description>The clinical course and prognostic factors of HER2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. The aim of this study was to determine prognostic factors associated with HER2-positive patients who develop brain metastases. This retrospective study assessed the largest dataset to date of 432 HER2-positive patients who were diagnosed with brain metastases from 24 institutions of the Japan Clinical Oncology Group, Breast Cancer Study Group. The median age of the 432 patients was 54 years (range, 20–86 years). Of the patients, 162 patients (37.5 %) had ER-positive/HER2-positive (ER+HER2+) breast cancer, and 270 (62.5 %) had ER-negative/HER2-positive (ER−HER2+) breast cancer. The median brain metastasis-free survival period from primary breast cancer was 33.5 months in both groups. The median survival after developing brain metastasis was 16.5 and 11.5 months in the ER+HER2+ and ER−HER2+ groups, respectively, (
p
= 0.117). Patients with >3 brain metastases had significantly shorter overall survival in both ER+HER2+ (
p
< 0.001) and ER−HER2+ (
p
= 0.018) groups. Treatment with trastuzumab before developing brain metastases was not associated with survival duration after developing brain metastases (
p
= 0.571). However, patients treated with both trastuzumab and lapatinib after developing metastasis had significantly longer survival than patients treated with trastuzumab alone, lapatinib alone, or no HER2-targeting agent (
p
< 0.001). For HER2-positive patients with brain metastases, regardless of the use of trastuzumab before developing brain metastasis, treatment with both trastuzumab and lapatinib might improve survival.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-014-3237-7</identifier><identifier>PMID: 25528021</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - administration & dosage ; Brain ; Brain Neoplasms - drug therapy ; Brain Neoplasms - epidemiology ; Brain Neoplasms - pathology ; Brain Neoplasms - secondary ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Cancer patients ; Cancer research ; Cancer therapies ; Disease-Free Survival ; Epidemiology ; Epidermal growth factor ; Female ; Health aspects ; Humans ; Japan ; Kaplan-Meier Estimate ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Oncology ; Prognosis ; Quinazolines - administration & dosage ; Receptor, ErbB-2 - antagonists & inhibitors ; Receptor, ErbB-2 - genetics ; Retrospective Studies ; Trastuzumab</subject><ispartof>Breast cancer research and treatment, 2015-01, Vol.149 (1), p.277-284</ispartof><rights>Springer Science+Business Media New York 2014</rights><rights>COPYRIGHT 2015 Springer</rights><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c606t-aedde120c5996051f7e2c366f6578020d81f63bd52995d9684516a43d890163d3</citedby><cites>FETCH-LOGICAL-c606t-aedde120c5996051f7e2c366f6578020d81f63bd52995d9684516a43d890163d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-014-3237-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-014-3237-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25528021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayashi, Naoki</creatorcontrib><creatorcontrib>Niikura, Naoki</creatorcontrib><creatorcontrib>Masuda, Norikazu</creatorcontrib><creatorcontrib>Takashima, Seiki</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Kanbayashi, Chizuko</creatorcontrib><creatorcontrib>Ishida, Mayumi</creatorcontrib><creatorcontrib>Hozumi, Yasuo</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Honda, Yayoi</creatorcontrib><creatorcontrib>Matsui, Akira</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Oshitanai, Risa</creatorcontrib><creatorcontrib>Yasojima, Hiroyuki</creatorcontrib><creatorcontrib>Yamauchi, Hideko</creatorcontrib><creatorcontrib>Saji, Shigehira</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><title>Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The clinical course and prognostic factors of HER2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. The aim of this study was to determine prognostic factors associated with HER2-positive patients who develop brain metastases. This retrospective study assessed the largest dataset to date of 432 HER2-positive patients who were diagnosed with brain metastases from 24 institutions of the Japan Clinical Oncology Group, Breast Cancer Study Group. The median age of the 432 patients was 54 years (range, 20–86 years). Of the patients, 162 patients (37.5 %) had ER-positive/HER2-positive (ER+HER2+) breast cancer, and 270 (62.5 %) had ER-negative/HER2-positive (ER−HER2+) breast cancer. The median brain metastasis-free survival period from primary breast cancer was 33.5 months in both groups. The median survival after developing brain metastasis was 16.5 and 11.5 months in the ER+HER2+ and ER−HER2+ groups, respectively, (
p
= 0.117). Patients with >3 brain metastases had significantly shorter overall survival in both ER+HER2+ (
p
< 0.001) and ER−HER2+ (
p
= 0.018) groups. Treatment with trastuzumab before developing brain metastases was not associated with survival duration after developing brain metastases (
p
= 0.571). However, patients treated with both trastuzumab and lapatinib after developing metastasis had significantly longer survival than patients treated with trastuzumab alone, lapatinib alone, or no HER2-targeting agent (
p
< 0.001). For HER2-positive patients with brain metastases, regardless of the use of trastuzumab before developing brain metastasis, treatment with both trastuzumab and lapatinib might improve survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Brain</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - epidemiology</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - secondary</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Disease-Free Survival</subject><subject>Epidemiology</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Japan</subject><subject>Kaplan-Meier Estimate</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Quinazolines - administration & dosage</subject><subject>Receptor, ErbB-2 - antagonists & inhibitors</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Retrospective Studies</subject><subject>Trastuzumab</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kk9rFTEUxQdR7LP6AdxIQBA3U_NnkkzcldJaoaCIrkNecue9lJlkTDItXfjdm-er2oqSRSD5ncM9l9M0Lwk-IhjLd5lg3qkWk65llMlWPmpWhEvWSkrk42aFiZCt6LE4aJ7lfIkxVhKrp80B5Zz2mJJV8-NzipsQc_EWDcaWmDKKAzo__ULbOWZf_BWgdQKTC7ImWEhoNsVDKBldbyNycAVjnCtifEATlAqa7PN7ZNC0jNW2olWUoKSYZ7A_DU0w402lnjdPBjNmeHF3Hzbfzk6_npy3F58-fDw5vmitwKK0BpwDQrHlSgnMySCBWibEILisMbDrySDY2nGqFHdK9B0nwnTM9aqugDl22Lzd-84pfl8gFz35bGEcTYC4ZE0Ep0xJ3ncVff0XehmXVOfdUZ3gnHW0_0NtzAjahyGWZOzOVB93WCmpCFWVOvoHVY-DydsYYPD1_YHgzT3BFsxYtjmOS_Ex5Icg2YO2bjUnGPSc_GTSjSZY77qh993QtRt61w0tq-bVXbJlPYH7rfhVhgrQPZDrV9hAuhf9v663ru3CZA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Hayashi, Naoki</creator><creator>Niikura, Naoki</creator><creator>Masuda, Norikazu</creator><creator>Takashima, Seiki</creator><creator>Nakamura, Rikiya</creator><creator>Watanabe, Ken-ichi</creator><creator>Kanbayashi, Chizuko</creator><creator>Ishida, Mayumi</creator><creator>Hozumi, Yasuo</creator><creator>Tsuneizumi, Michiko</creator><creator>Kondo, Naoto</creator><creator>Naito, Yoichi</creator><creator>Honda, Yayoi</creator><creator>Matsui, Akira</creator><creator>Fujisawa, Tomomi</creator><creator>Oshitanai, Risa</creator><creator>Yasojima, Hiroyuki</creator><creator>Yamauchi, Hideko</creator><creator>Saji, Shigehira</creator><creator>Iwata, Hiroji</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis</title><author>Hayashi, Naoki ; Niikura, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Yamauchi, Hideko ; Saji, Shigehira ; Iwata, Hiroji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c606t-aedde120c5996051f7e2c366f6578020d81f63bd52995d9684516a43d890163d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Brain</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - epidemiology</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - secondary</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Disease-Free Survival</topic><topic>Epidemiology</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Japan</topic><topic>Kaplan-Meier Estimate</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Quinazolines - administration & dosage</topic><topic>Receptor, ErbB-2 - antagonists & inhibitors</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Retrospective Studies</topic><topic>Trastuzumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayashi, Naoki</creatorcontrib><creatorcontrib>Niikura, Naoki</creatorcontrib><creatorcontrib>Masuda, Norikazu</creatorcontrib><creatorcontrib>Takashima, Seiki</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Kanbayashi, Chizuko</creatorcontrib><creatorcontrib>Ishida, Mayumi</creatorcontrib><creatorcontrib>Hozumi, Yasuo</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Honda, Yayoi</creatorcontrib><creatorcontrib>Matsui, Akira</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Oshitanai, Risa</creatorcontrib><creatorcontrib>Yasojima, Hiroyuki</creatorcontrib><creatorcontrib>Yamauchi, Hideko</creatorcontrib><creatorcontrib>Saji, Shigehira</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayashi, Naoki</au><au>Niikura, Naoki</au><au>Masuda, Norikazu</au><au>Takashima, Seiki</au><au>Nakamura, Rikiya</au><au>Watanabe, Ken-ichi</au><au>Kanbayashi, Chizuko</au><au>Ishida, Mayumi</au><au>Hozumi, Yasuo</au><au>Tsuneizumi, Michiko</au><au>Kondo, Naoto</au><au>Naito, Yoichi</au><au>Honda, Yayoi</au><au>Matsui, Akira</au><au>Fujisawa, Tomomi</au><au>Oshitanai, Risa</au><au>Yasojima, Hiroyuki</au><au>Yamauchi, Hideko</au><au>Saji, Shigehira</au><au>Iwata, Hiroji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>149</volume><issue>1</issue><spage>277</spage><epage>284</epage><pages>277-284</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The clinical course and prognostic factors of HER2-positive breast cancer patients with brain metastases are not well known because of the relatively small population. The aim of this study was to determine prognostic factors associated with HER2-positive patients who develop brain metastases. This retrospective study assessed the largest dataset to date of 432 HER2-positive patients who were diagnosed with brain metastases from 24 institutions of the Japan Clinical Oncology Group, Breast Cancer Study Group. The median age of the 432 patients was 54 years (range, 20–86 years). Of the patients, 162 patients (37.5 %) had ER-positive/HER2-positive (ER+HER2+) breast cancer, and 270 (62.5 %) had ER-negative/HER2-positive (ER−HER2+) breast cancer. The median brain metastasis-free survival period from primary breast cancer was 33.5 months in both groups. The median survival after developing brain metastasis was 16.5 and 11.5 months in the ER+HER2+ and ER−HER2+ groups, respectively, (
p
= 0.117). Patients with >3 brain metastases had significantly shorter overall survival in both ER+HER2+ (
p
< 0.001) and ER−HER2+ (
p
= 0.018) groups. Treatment with trastuzumab before developing brain metastases was not associated with survival duration after developing brain metastases (
p
= 0.571). However, patients treated with both trastuzumab and lapatinib after developing metastasis had significantly longer survival than patients treated with trastuzumab alone, lapatinib alone, or no HER2-targeting agent (
p
< 0.001). For HER2-positive patients with brain metastases, regardless of the use of trastuzumab before developing brain metastasis, treatment with both trastuzumab and lapatinib might improve survival.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>25528021</pmid><doi>10.1007/s10549-014-3237-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2015-01, Vol.149 (1), p.277-284 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652397584 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Brain Brain Neoplasms - drug therapy Brain Neoplasms - epidemiology Brain Neoplasms - pathology Brain Neoplasms - secondary Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - pathology Cancer patients Cancer research Cancer therapies Disease-Free Survival Epidemiology Epidermal growth factor Female Health aspects Humans Japan Kaplan-Meier Estimate Medical prognosis Medicine Medicine & Public Health Metastasis Middle Aged Oncology Prognosis Quinazolines - administration & dosage Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - genetics Retrospective Studies Trastuzumab |
| title | Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A45%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20of%20HER2-positive%20breast%20cancer%20patients%20who%20develop%20brain%20metastasis:%20a%20multicenter%20retrospective%20analysis&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Hayashi,%20Naoki&rft.date=2015-01-01&rft.volume=149&rft.issue=1&rft.spage=277&rft.epage=284&rft.pages=277-284&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-014-3237-7&rft_dat=%3Cgale_proqu%3EA409979129%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1646553428&rft_id=info:pmid/25528021&rft_galeid=A409979129&rfr_iscdi=true |